| Identification | Back Directory | [Name]
Vopratelimab | [CAS]
2039148-04-2 | [Synonyms]
Vopratelimab
Vopratelimab (anti-ICOS)
Research Grade Vopratelimab
Research Grade Vopratelimab (DHJ92101) |
| Hazard Information | Back Directory | [Uses]
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1]. | [in vivo]
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model[1]. | Animal Model: | Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1] | | Dosage: | 0.25-0.3 mg/kg | | Administration: | Intraperitoneal injection; twice a week, for 2 weeks | | Result: | Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model. |
| [References]
[1] Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595. DOI:10.1371/journal.pone.0239595 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|